A public health action plan is needed for chronic kidney disease

被引:22
作者
Schoolwerth, AC
Engelgau, MM
Hostetter, TH
机构
[1] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA
[2] Dartmouth Coll Sch Med, Sect Hypertens & Nephrol, Hanover, NH USA
[3] NIDDKD, Natl Kidney Dis Educ Program, NIH, Bethesda, MD USA
关键词
kidney disease; public health; surveillance; prevention; outcomes; end-stage renal disease;
D O I
10.1053/j.ackd.2005.07.012
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
In 2005, chronic kidney disease (CKD) meets all criteria for classification as a public health problem in the United States. It imposes a large burden on society that is increasing despite ongoing efforts to control the disease. The burden is unevenly distributed by race and economic status, whereas evidence suggests that preventive strategies could substantially reduce the burden. Finally, there are indications that such strategies are not yet in place. A broad and coordinated public health approach to the burgeoning health, economic, and societal challenges of CKD is needed to complement present clinical approaches, increase awareness, promote early detection, and facilitate prevention and treatment. (c) 2005 by the National Kidney Foundation, Inc.
引用
收藏
页码:418 / 423
页数:6
相关论文
共 49 条
[1]
Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365
[2]
[Anonymous], 2004, DIABETES CARE, DOI DOI 10.2337/DIACARE.27.5.1240-A
[3]
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[4]
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [J].
Bianchi, S ;
Bigazzi, R ;
Caiazza, A ;
Campese, VM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :565-570
[5]
Screening for proteinuria in US adults - A cost-effectiveness analysis [J].
Boulware, LE ;
Jaar, BG ;
Tarver-Carr, ME ;
Brancati, FL ;
Powe, NR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (23) :3101-3114
[6]
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[7]
Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P918
[8]
Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000 [J].
Coresh, J ;
Byrd-Holt, D ;
Astor, BC ;
Briggs, JP ;
Eggers, PW ;
Lacher, DA ;
Hostetter, TH .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (01) :180-188
[9]
Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey [J].
Coresh, J ;
Astor, BC ;
Greene, T ;
Eknoyan, G ;
Levey, AS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (01) :1-12
[10]
From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria [J].
de Jong, PE ;
Brenner, BM .
KIDNEY INTERNATIONAL, 2004, 66 (06) :2109-2118